Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Recently, on clinicaltrials.gov, Merck & Co Inc (NYSE:MRK) posted a new trial of Moderna Inc’s (NASDAQ:MRNA) V94...
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated ap...
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fe...
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday. Shares of NICE Ltd. (NASDAQ: NICE) rose sharply during Thursday&rs...
Moderna Inc (NASDAQ:MRNA) shares are trading higher after the company reported fourth-quarter 2023 revenues of $2.81 billion in Spikevax (COVI...
Investors pinned hopes on Nvidia Corp.’s (NASDAQ:NVDA) earnings to reinvigorate market momentum, and the AI leader delivered an impressive ...
Moderna, Inc. (NASDAQ: MRNA) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 22, 2024. Analysts exp...
Moderna Inc (NASDAQ:MRNA) shares are trading lower after a longer-term trial analysis revealed a faster decline in the effectiveness of its ex...
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...